Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.
Valuation and Earnings
This table compares Larimar Therapeutics and Enanta Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Larimar Therapeutics | N/A | N/A | -$165.67 million | ($2.06) | -1.69 |
| Enanta Pharmaceuticals | $69.21 million | 5.53 | -$81.89 million | ($2.59) | -5.08 |
Profitability
This table compares Larimar Therapeutics and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Larimar Therapeutics | N/A | -134.14% | -96.00% |
| Enanta Pharmaceuticals | -89.56% | -64.04% | -20.22% |
Risk and Volatility
Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Institutional & Insider Ownership
91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Larimar Therapeutics and Enanta Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Larimar Therapeutics | 1 | 0 | 7 | 3 | 3.09 |
| Enanta Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
Larimar Therapeutics currently has a consensus target price of $15.29, indicating a potential upside of 339.24%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 54.15%. Given Larimar Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Enanta Pharmaceuticals.
Summary
Enanta Pharmaceuticals beats Larimar Therapeutics on 7 of the 13 factors compared between the two stocks.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
